Mateon Therapeutics Stock Price, News & Analysis (OTCMKTS:MATN)

$0.24 -0.02 (-6.00 %)
(As of 11/17/2017 10:50 AM ET)
Previous Close$0.24
Today's Range$0.19 - $0.27
52-Week Range$0.16 - $0.89
Volume227,134 shs
Average Volume23,247 shs
Market Capitalization$6.23 million
P/E RatioN/A
Dividend YieldN/A

About Mateon Therapeutics (OTCMKTS:MATN)

Mateon Therapeutics logoMateon Therapeutics, Inc., formerly OXiGENE, Inc., is a biopharmaceutical company. The Company is focused on the development of vascular disrupting agents (VDAs) for the treatment of cancer. The Company is engaged in developing two clinical stage investigational drugs: VDAs-CA4P and OXi4503. Its lead compound is CA4P, which is also known as combretastatin A4-phosphate, fosbretabulin tromethamine, fosbretabulin and ZYBRESTAT. VDAs selectively targets the vasculature of cancer tumors and obstructs a tumor's blood supply without disrupting the blood supply to normal tissues. VDAs are in a class of drugs called vascular targeted therapies (VTTs), which also includes anti-angiogenic agents (AAs). CA4P is a reversible tubulin binding agent that selectively targets the endothelial cells that make up the blood vessel walls in solid tumors. The Company is pursuing the development of a product candidate, OXi4503, which is a dual-mechanism VDA.

Industry, Sector and Symbol:
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Sector: Medical
  • Symbol: OTCMKTS:MATN
  • Previous Symbol: NASDAQ:MATN
  • CUSIP: N/A
  • Web:
  • Current Ratio: 4.57%
  • Quick Ratio: 4.57%
Sales & Book Value:
  • Annual Sales: N/A
  • Price / Sales: N/A
  • Book Value: $0.47 per share
  • Price / Book: 0.50
  • Trailing EPS: ($0.55)
  • Net Income: ($13,650,000.00)
  • Return on Equity: -168.66%
  • Return on Assets: -144.46%
  • Employees: 16
  • Outstanding Shares: 26,550,000

Frequently Asked Questions for Mateon Therapeutics (OTCMKTS:MATN)

What is Mateon Therapeutics' stock symbol?

Mateon Therapeutics trades on the OTCMKTS under the ticker symbol "MATN."

How were Mateon Therapeutics' earnings last quarter?

Mateon Therapeutics, Inc. (OTCMKTS:MATN) released its earnings results on Tuesday, November, 14th. The biopharmaceutical company reported ($0.13) earnings per share for the quarter. View Mateon Therapeutics' Earnings History.

Where is Mateon Therapeutics' stock going? Where will Mateon Therapeutics' stock price be in 2017?

4 brokers have issued 12 month price objectives for Mateon Therapeutics' stock. Their predictions range from $2.00 to $2.00. On average, they anticipate Mateon Therapeutics' share price to reach $2.00 in the next year. View Analyst Ratings for Mateon Therapeutics.

Who are some of Mateon Therapeutics' key competitors?

Who are Mateon Therapeutics' key executives?

Mateon Therapeutics' management team includes the folowing people:

  • William D. Schwieterman M.D., Chairman of the Board, President, Chief Executive Officer (Age 58)
  • Matthew M. Loar CPA, Chief Financial Officer, Principal Accounting Officer (Age 51)
  • David Chaplin Ph.D., Chief Scientific Officer, Director (Age 59)
  • Simon C Pedder Ph.D., Director (Age 56)
  • Donald R. Reynolds, Independent Director (Age 54)
  • Bobby W. Sandage Jr., Ph.D., Independent Director (Age 63)

How do I buy Mateon Therapeutics stock?

Shares of Mateon Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Mateon Therapeutics' stock price today?

One share of Mateon Therapeutics stock can currently be purchased for approximately $0.24.

How big of a company is Mateon Therapeutics?

Mateon Therapeutics has a market capitalization of $6.23 million. The biopharmaceutical company earns ($13,650,000.00) in net income (profit) each year or ($0.55) on an earnings per share basis. Mateon Therapeutics employs 16 workers across the globe.

How can I contact Mateon Therapeutics?

Mateon Therapeutics' mailing address is 701 Gateway Blvd Ste 210, SOUTH SAN FRANCISCO, CA 94080-7041, United States. The biopharmaceutical company can be reached via phone at +1-650-6357000 or via email at [email protected]

MarketBeat Community Rating for Mateon Therapeutics (OTCMKTS MATN)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  96 (Vote Outperform)
Underperform Votes:  77 (Vote Underperform)
Total Votes:  173
MarketBeat's community ratings are surveys of what our community members think about Mateon Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Mateon Therapeutics (OTCMKTS:MATN)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 1 Hold Rating, 3 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 2.75)
Consensus Price Target: $2.00

Consensus Price Target History for Mateon Therapeutics (OTCMKTS:MATN)

Price Target History for Mateon Therapeutics (OTCMKTS:MATN)

Analysts' Ratings History for Mateon Therapeutics (OTCMKTS:MATN)

DateFirmActionRatingPrice TargetDetails
8/1/2017Maxim GroupReiterated RatingHoldView Rating Details
4/20/2017Roth CapitalInitiated CoverageBuy -> Buy$2.00View Rating Details
3/13/2017HC WainwrightInitiated CoverageBuy$2.00View Rating Details
3/13/2017Rodman & RenshawReiterated RatingBuy -> Buy$2.00View Rating Details
1/29/2016S&P Equity ResearchLower Price Target$0.64 -> $0.58View Rating Details
(Data available from 11/18/2015 forward)


Earnings History and Estimates Chart for Mateon Therapeutics (OTCMKTS:MATN)

Earnings by Quarter for Mateon Therapeutics (OTCMKTS:MATN)

Earnings History by Quarter for Mateon Therapeutics (OTCMKTS MATN)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/14/2017Q3 2017($0.13)ViewN/AView Earnings Details
8/2/2017Q2 2017($0.12)($0.15)ViewN/AView Earnings Details
5/8/2017Q1 2017($0.13)($0.15)ViewN/AView Earnings Details
3/30/2017Q4 2016($0.13)($0.13)ViewN/AView Earnings Details
11/14/2016Q3 2016($0.15)($0.12)ViewN/AView Earnings Details
5/9/2016Q116($0.19)($0.13)ViewN/AView Earnings Details
11/10/2015Q3($0.13)($0.14)ViewN/AView Earnings Details
8/4/2015Q215($0.10)($0.13)ViewN/AView Earnings Details
4/30/2015Q115($0.13)($0.13)ViewN/AView Earnings Details
4/14/2015($0.13)($0.11)ViewN/AView Earnings Details
3/17/2015Q414($0.17)($0.11)ViewN/AView Earnings Details
11/12/2014Q3($0.23)($0.17)ViewListenView Earnings Details
8/5/2014Q2 2014($0.13)($0.23)ViewN/AView Earnings Details
5/6/2014Q1 2014($0.19)($0.29)ViewN/AView Earnings Details
3/18/2014Q412($4.67)ViewN/AView Earnings Details
11/12/2013Q3($1.88)ViewListenView Earnings Details
11/8/2012Q312($0.13)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Mateon Therapeutics (OTCMKTS:MATN)

No earnings estimates for this company have been tracked by


Dividend History for Mateon Therapeutics (OTCMKTS:MATN)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Mateon Therapeutics (OTCMKTS MATN)

Insider Ownership Percentage: 4.50%
Insider Trades by Quarter for Mateon Therapeutics (OTCMKTS:MATN)

Insider Trades by Quarter for Mateon Therapeutics (OTCMKTS MATN)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/16/2016Donald Rogers ReynoldsDirectorBuy30,000$0.35$10,500.00View SEC Filing  
6/28/2013Peter LangeckerCEOBuy3,000$2.75$8,250.00View SEC Filing  
6/25/2013Peter LangeckerCEOBuy2,000$2.79$5,580.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Mateon Therapeutics (OTCMKTS:MATN)

Latest Headlines for Mateon Therapeutics (OTCMKTS MATN)


Social Media



Mateon Therapeutics (OTCMKTS MATN) Chart for Saturday, November, 18, 2017
Loading chart…

This page was last updated on 11/18/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.